Transcarent
Health benefits navigation and care platform for self insured employers and health plans, indexed for its AI navigation layer with the surrounding care services as context. WayFinding is a generative AI experience launched in 2024 and scaled through 2025, combining benefits navigation, clinical guidance, and care access in one interface, delivering tailored recommendations from a member's own history so a member can determine what is covered, what it will cost, and where to go. Agentic capabilities were added in January 2026. The company completed a $621 million merger with Accolade in April 2025, taking the formerly NASDAQ listed company private and combining WayFinding and the Cancer Care, Surgery Care, Weight Health, and pharmacy benefit experiences with Accolade's health advocacy, expert medical opinion, virtual primary care, and its True Health Actions platform, which draws on employer data, health plan data, and electronic health records for targeted guidance. The combined organization reports serving more than 20 million members across more than 1,700 employer and health plan clients. Buyers should be clear that this is a hybrid: a substantial share of what is delivered is human advocacy, virtual clinical care, and second opinion services rather than AI. A $126 million Series D in May 2024 was raised specifically to build AI capability. Led by Glen Tullman.
Capability Axes
WayFinding is genuine generative AI and the company raised a $126 million round specifically to build the capability, but the delivered product is substantially human: advocacy, expert medical opinion, virtual primary care, and staffed care experiences for cancer, surgery, and weight, most of it acquired with Accolade. The AI is the navigation surface over a large services organization. Buyers should scope which layer they are actually purchasing, since the economics of an AI interface and a staffed advocacy service differ entirely.
Agentic capabilities were added to WayFinding in January 2026, and no escalation criteria, confidence thresholds, or human review gates were retrieved for them. The consequence surface deserves attention: a member asking what is covered and what it will cost is receiving guidance with financial consequence, and one that steers toward or away from care has clinical consequence too. The company does employ large advocacy and clinical teams who represent a natural escalation path, but the criteria for routing to them are not published.
Scale is not in question: more than 20 million members across more than 1,700 employer and health plan clients following the April 2025 Accolade merger. Held back from A because that scale is the combined footprint of two established benefits businesses rather than evidence for WayFinding specifically, which reached full deployment only in 2025, and no utilization, accuracy, or cost outcome data attributable to the AI layer was retrieved. This is the same distinction applied to Medable, Medidata, and Veeva: platform scale is not evidence for a recent AI capability.
The True Health Actions platform acquired with Accolade draws on employer data, health plan data, and electronic health records to generate targeted guidance, which is a broader data foundation than benefits eligibility alone and is what makes personalization more than plan document lookup. Held back from A because named EHR integrations and data acquisition methods were not retrieved.
No public pricing. Contact the vendor. Sold to self insured employers and health plans, typically per member per month with additional fees for staffed care experiences. Buyers should separate the navigation platform from the services layers, since the merger bundled two previously distinct purchases and the combined offer may price capabilities a given employer does not need.
Bounded to the employer and health plan benefits context rather than clinical settings, spanning benefits navigation, pharmacy benefit, and staffed care experiences in cancer, surgery, and weight health, extended by the merger into advocacy, expert medical opinion, virtual primary care, and partner mental health services. Held back from A because the range spans navigation, clinical delivery, and benefits administration, and maturity across those is unlikely to be uniform.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Per member per month employer and health plan agreements; services priced separately | — | — | Third Party Estimated |
No rate card published. Sold to self insured employers and health plans, typically on a per member per month basis with additional charges for staffed care experiences. The April 2025 Accolade merger combined two previously separate purchases, so an employer evaluating the platform should unbundle deliberately: the AI navigation layer, the advocacy and expert medical opinion services, virtual primary care, and the condition specific care experiences were distinct products until recently and carry very different cost structures. Establish which components are contractually required versus optional.